Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.

Hdl Handle:
http://hdl.handle.net/10147/323400
Title:
Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.
Authors:
Yang, James Chih-Hsin; Hirsh, Vera; Schuler, Martin; Yamamoto, Nobuyuki; O'Byrne, Kenneth J; Mok, Tony S K; Zazulina, Victoria; Shahidi, Mehdi; Lungershausen, Juliane; Massey, Dan; Palmer, Michael; Sequist, Lecia V
Affiliation:
James Chih-Hsin Yang, National Taiwan University Hospital, Taipei, Taiwan; Vera Hirsh, McGill University, Montreal, Quebec, Canada; Martin Schuler, West German Cancer Center, University Duisburg-Essen, Essen; Juliane Lungershausen, Boehringer Ingelheim GmbH, Ingelheim, Germany; Nobuyuki Yamamoto, Shizuoka Cancer Center, Shizuoka, Japan; Kenneth J. O'Byrne, St James' Hospital, Dublin, Ireland; Tony S.K. Mok, State Key Laboratory of Southern China, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong; Victoria Zazulina, Mehdi Shahidi, and Dan Massey, Boehringer Ingelheim Limited, Bracknell; Michael Palmer, Keele University, Keele, United Kingdom; and Lecia V. Sequist, Massachusetts General Hospital and Harvard Medical School, Boston, MA.
Citation:
Yang JCH et al. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J. Clin. Oncol.2013, 31 (27):3342-50
Journal:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Issue Date:
20-Sep-2013
URI:
http://hdl.handle.net/10147/323400
DOI:
10.1200/JCO.2012.46.1764
PubMed ID:
23816967
Abstract:
Patient-reported symptoms and health-related quality of life (QoL) benefits were investigated in a randomized, phase III trial of afatinib or cisplatin/pemetrexed.
Item Type:
Article
Language:
en
Keywords:
LUNG CANCER; QUALITY OF LIFE
MeSH:
Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Glutamates; Guanine; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Quality of Life; Quinazolines; Receptor, Epidermal Growth Factor; Treatment Outcome
ISSN:
1527-7755

Full metadata record

DC FieldValue Language
dc.contributor.authorYang, James Chih-Hsinen_GB
dc.contributor.authorHirsh, Veraen_GB
dc.contributor.authorSchuler, Martinen_GB
dc.contributor.authorYamamoto, Nobuyukien_GB
dc.contributor.authorO'Byrne, Kenneth Jen_GB
dc.contributor.authorMok, Tony S Ken_GB
dc.contributor.authorZazulina, Victoriaen_GB
dc.contributor.authorShahidi, Mehdien_GB
dc.contributor.authorLungershausen, Julianeen_GB
dc.contributor.authorMassey, Danen_GB
dc.contributor.authorPalmer, Michaelen_GB
dc.contributor.authorSequist, Lecia Ven_GB
dc.date.accessioned2014-07-18T10:34:25Z-
dc.date.available2014-07-18T10:34:25Z-
dc.date.issued2013-09-20-
dc.identifier.citationYang JCH et al. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J. Clin. Oncol.2013, 31 (27):3342-50en_GB
dc.identifier.issn1527-7755-
dc.identifier.pmid23816967-
dc.identifier.doi10.1200/JCO.2012.46.1764-
dc.identifier.urihttp://hdl.handle.net/10147/323400-
dc.description.abstractPatient-reported symptoms and health-related quality of life (QoL) benefits were investigated in a randomized, phase III trial of afatinib or cisplatin/pemetrexed.en_GB
dc.language.isoenen
dc.rightsArchived with thanks to Journal of clinical oncology : official journal of the American Society of Clinical Oncologyen_GB
dc.subjectLUNG CANCERen_GB
dc.subjectQUALITY OF LIFEen_GB
dc.subject.meshAdenocarcinoma-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshCisplatin-
dc.subject.meshGlutamates-
dc.subject.meshGuanine-
dc.subject.meshHumans-
dc.subject.meshLung Neoplasms-
dc.subject.meshMutation-
dc.subject.meshNeoplasm Staging-
dc.subject.meshQuality of Life-
dc.subject.meshQuinazolines-
dc.subject.meshReceptor, Epidermal Growth Factor-
dc.subject.meshTreatment Outcome-
dc.titleSymptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.en_GB
dc.typeArticleen
dc.contributor.departmentJames Chih-Hsin Yang, National Taiwan University Hospital, Taipei, Taiwan; Vera Hirsh, McGill University, Montreal, Quebec, Canada; Martin Schuler, West German Cancer Center, University Duisburg-Essen, Essen; Juliane Lungershausen, Boehringer Ingelheim GmbH, Ingelheim, Germany; Nobuyuki Yamamoto, Shizuoka Cancer Center, Shizuoka, Japan; Kenneth J. O'Byrne, St James' Hospital, Dublin, Ireland; Tony S.K. Mok, State Key Laboratory of Southern China, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong; Victoria Zazulina, Mehdi Shahidi, and Dan Massey, Boehringer Ingelheim Limited, Bracknell; Michael Palmer, Keele University, Keele, United Kingdom; and Lecia V. Sequist, Massachusetts General Hospital and Harvard Medical School, Boston, MA.en_GB
dc.identifier.journalJournal of clinical oncology : official journal of the American Society of Clinical Oncologyen_GB
dc.description.fundingNo fundingen
dc.description.provinceLeinsteren
dc.description.peer-reviewpeer-reviewen

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.